The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery Contract (IDC) to Merck Sharp & Dohme LLC, doing business as Merck, with a ceiling value of $4,116,159,200. This multiple-award IDC is to support the Vaccines for Children (VFC) program, which provides immunizations to eligible children who are Medicaid-eligible, uninsured, American Indian/Alaska Native, or have insurance that does not cover vaccines.
As a vaccine manufacturer, Merck will provide a range of standard commercial pediatric vaccines, including those for measles, mumps, rubella, varicella, hepatitis, pneumococcal, tetanus, diphtheria, human papillomavirus, and meningococcal diseases. The contract period is 12 months, from April 1, 2025, to March 31, 2026, with delivery of vaccines required within 15 working days to CDC distribution centers. The solicitation, which had no set-aside designation, evaluated offers based on technical capability, pricing, and past performance. Merck, as a for-profit organization and manufacturer of goods, is a critical partner in supplying essential pharmaceutical products to support the CDC's public health initiatives and immunization programs.
Generated 3/25/25, 9:48 AM